{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:37:43Z","timestamp":1777412263817,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["2024J011222"],"award-info":[{"award-number":["2024J011222"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Fujian Natural Science Foundation","doi-asserted-by":"crossref","award":["2021J011290"],"award-info":[{"award-number":["2021J011290"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"name":"China Hepatitis Prevention and Treatment Foundation Tianqing Liver Disease Research Fund","award":["TQGB20210098"],"award-info":[{"award-number":["TQGB20210098"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-32228-y","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T02:04:40Z","timestamp":1765850680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Apatinib-Induced STAT1\/NK axis activation augments PD-1 inhibitor efficacy in advanced Hepatocellular Carcinoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Lin-sheng","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-ru","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie-ru","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-zhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luo-bin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-shi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-sen","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"32228_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","volume":"156","author":"L Kulik","year":"2019","unstructured":"Kulik, L. & El-Serag, H. B. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 156, 477\u2013491e1 (2019).","journal-title":"Gastroenterology"},{"key":"32228_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"32228_CR3","doi-asserted-by":"publisher","first-page":"1070961","DOI":"10.3389\/fimmu.2022.1070961","volume":"13","author":"Q Li","year":"2022","unstructured":"Li, Q., Han, J., Yang, Y. & Chen, Y. PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front. Immunol. 13, 1070961 (2022).","journal-title":"Front. Immunol."},{"key":"32228_CR4","doi-asserted-by":"publisher","first-page":"11091","DOI":"10.3390\/ijms252011091","volume":"25","author":"A Rizzo","year":"2024","unstructured":"Rizzo, A., Brunetti, O. & Brandi, G. Hepatocellular carcinoma immunotherapy: predictors of Response, Issues, and challenges. Int. J. Mol. Sci. 25, 11091 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"32228_CR5","doi-asserted-by":"publisher","first-page":"216726","DOI":"10.1016\/j.canlet.2024.216726","volume":"588","author":"M Gao","year":"2024","unstructured":"Gao, M. et al. PD-1 regulation in immune homeostasis and immunotherapy. Cancer Lett. 588, 216726 (2024).","journal-title":"Cancer Lett."},{"key":"32228_CR6","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.3390\/ijms22115801","volume":"22","author":"K Oura","year":"2021","unstructured":"Oura, K., Morishita, A., Tani, J. & Masaki, T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: A review. Int. J. Mol. Sci. 22, 5801 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"32228_CR7","doi-asserted-by":"publisher","first-page":"783236","DOI":"10.3389\/fimmu.2021.783236","volume":"12","author":"R Xing","year":"2021","unstructured":"Xing, R., Gao, J., Cui, Q. & Wang, Q. Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma. Front. Immunol. 12, 783236 (2021).","journal-title":"Front. Immunol."},{"key":"32228_CR8","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/s41467-023-37727-y","volume":"14","author":"B Palakurthi","year":"2023","unstructured":"Palakurthi, B. et al. Targeting CXCL16 and STAT1 augments immune checkpoint Blockade therapy in triple-negative breast cancer. Nat. Commun. 14, 2109 (2023).","journal-title":"Nat. Commun."},{"key":"32228_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41568-022-00537-3","volume":"23","author":"Y-J Li","year":"2023","unstructured":"Li, Y-J., Zhang, C., Martincuks, A., Herrmann, A. & Yu, H. STAT proteins in cancer: orchestration of metabolism. Nat. Rev. Cancer. 23, 115\u2013134 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"32228_CR10","doi-asserted-by":"publisher","first-page":"e005684","DOI":"10.1136\/jitc-2022-005684","volume":"10","author":"NI Khushalani","year":"2022","unstructured":"Khushalani, N. I. et al. Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. J. Immunother Cancer. 10, e005684 (2022).","journal-title":"J. Immunother Cancer"},{"key":"32228_CR11","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-23-0215","volume":"29","author":"B Horowitch","year":"2023","unstructured":"Horowitch, B. et al. Subsets of IFN signaling predict response to immune checkpoint Blockade in patients with melanoma. Clin. Cancer Res. 29, 2908\u20132918 (2023).","journal-title":"Clin. Cancer Res."},{"key":"32228_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.semcancer.2022.08.003","volume":"86","author":"GL Wong","year":"2022","unstructured":"Wong, G. L., Manore, S. G., Doheny, D. L. & Lo, H-W. STAT family of transcription factors in breast cancer: pathogenesis and therapeutic opportunities and challenges. Semin Cancer Biol. 86, 84\u2013106 (2022).","journal-title":"Semin Cancer Biol."},{"key":"32228_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.semcancer.2019.10.002","volume":"60","author":"Y Verhoeven","year":"2020","unstructured":"Verhoeven, Y. et al. The potential and controversy of targeting STAT family members in cancer. Semin Cancer Biol. 60, 41\u201356 (2020).","journal-title":"Semin Cancer Biol."},{"key":"32228_CR14","doi-asserted-by":"publisher","first-page":"e007678","DOI":"10.1136\/jitc-2023-007678","volume":"11","author":"X Zheng","year":"2023","unstructured":"Zheng, X. et al. Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint Blockade through the NR2F1-STAT1 pathway. J. Immunother Cancer. 11, e007678 (2023).","journal-title":"J. Immunother Cancer"},{"key":"32228_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41417-020-0186-7","volume":"28","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma. Cancer Gene Ther. 28, 89\u201397 (2021).","journal-title":"Cancer Gene Ther."},{"key":"32228_CR16","doi-asserted-by":"publisher","first-page":"1190333","DOI":"10.3389\/fimmu.2023.1190333","volume":"14","author":"J Han","year":"2023","unstructured":"Han, J., Wu, M. & Liu, Z. Dysregulation in IFN-\u03b3 signaling and response: the barricade to tumor immunotherapy. Front. Immunol. 14, 1190333 (2023).","journal-title":"Front. Immunol."},{"key":"32228_CR17","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/hep.21419","volume":"44","author":"W-I Jeong","year":"2006","unstructured":"Jeong, W-I., Park, O., Radaeva, S. & Gao, B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 44, 1441\u20131451 (2006).","journal-title":"Hepatology"},{"key":"32228_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41392-025-02153-7","volume":"10","author":"M Liu","year":"2025","unstructured":"Liu, M. et al. Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial. Signal. Transduct. Target. Ther. 10, 65 (2025).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"32228_CR19","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Camrelizumab plus Rivoceranib versus Sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 402, 1133\u20131146 (2023).","journal-title":"Lancet"},{"key":"32228_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","volume":"14","author":"S Farkona","year":"2016","unstructured":"Farkona, S., Diamandis, E. P. & Blasutig, I. M. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 14, 73 (2016).","journal-title":"BMC Med."},{"key":"32228_CR21","doi-asserted-by":"publisher","first-page":"e004389","DOI":"10.1136\/jitc-2021-004389","volume":"10","author":"H Chen","year":"2022","unstructured":"Chen, H. et al. Personalized neoantigen vaccine combined with PD-1 Blockade increases CD8\u2009+\u2009tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models. J. Immunother Cancer. 10, e004389 (2022).","journal-title":"J. Immunother Cancer"},{"key":"32228_CR22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","volume":"8","author":"T-Q Zhang","year":"2023","unstructured":"Zhang, T-Q. et al. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona clinic liver cancer stage C (TRIPLET): a phase II study. Signal. Transduct. Target. Ther. 8, 413 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"32228_CR23","doi-asserted-by":"publisher","first-page":"937307","DOI":"10.3389\/fimmu.2022.937307","volume":"13","author":"H Li","year":"2022","unstructured":"Li, H. et al. Apatinib: A novel antiangiogenic drug in monotherapy or combination immunotherapy for digestive system malignancies. Front. Immunol. 13, 937307 (2022).","journal-title":"Front. Immunol."},{"key":"32228_CR24","doi-asserted-by":"publisher","first-page":"e008554","DOI":"10.1136\/jitc-2023-008554","volume":"12","author":"Q Tao","year":"2024","unstructured":"Tao, Q. et al. Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-\u03b3-STAT1-IRF1-LPCAT3-induced ferroptosis in tumors. J. Immunother Cancer. 12, e008554 (2024).","journal-title":"J. Immunother Cancer"},{"key":"32228_CR25","doi-asserted-by":"publisher","first-page":"eaav7816","DOI":"10.1126\/scitranslmed.aav7816","volume":"11","author":"RM Zemek","year":"2019","unstructured":"Zemek, R. M. et al. Sensitization to immune checkpoint Blockade through activation of a STAT1\/NK axis in the tumor microenvironment. Sci. Transl Med. 11, eaav7816 (2019).","journal-title":"Sci. Transl Med."},{"key":"32228_CR26","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1164\/rccm.202201-0142OC","volume":"206","author":"K Jandl","year":"2022","unstructured":"Jandl, K. et al. Impairment of the NKT-STAT1-CXCL9 axis contributes to vessel fibrosis in pulmonary hypertension caused by lung fibrosis. Am. J. Respir Crit. Care Med. 206, 981\u2013998 (2022).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"32228_CR27","unstructured":"Contribution of NK cells. to immunotherapy mediated by PD-1\/PD-L1 blockade - PubMed [Internet]. [cited 2024 Dec 16]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30198904\/"},{"key":"32228_CR28","doi-asserted-by":"publisher","first-page":"e005026","DOI":"10.1136\/jitc-2022-005026","volume":"10","author":"R Raja","year":"2022","unstructured":"Raja, R. et al. PP4 Inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling. J. Immunother Cancer. 10, e005026 (2022).","journal-title":"J. Immunother Cancer"},{"key":"32228_CR29","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.3389\/fimmu.2020.02189","volume":"11","author":"K Meissl","year":"2020","unstructured":"Meissl, K. et al. STAT1 isoforms differentially regulate NK cell maturation and Anti-tumor activity. Front. Immunol. 11, 2189 (2020).","journal-title":"Front. Immunol."},{"key":"32228_CR30","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","volume":"24","author":"KC Barry","year":"2018","unstructured":"Barry, K. C. et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat. Med. 24, 1178\u20131191 (2018).","journal-title":"Nat. Med."},{"key":"32228_CR31","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1172\/JCI132712","volume":"130","author":"M Lin","year":"2020","unstructured":"Lin, M. et al. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. J. Clin. Invest. 130, 2560\u20132569 (2020).","journal-title":"J. Clin. Invest."},{"key":"32228_CR32","doi-asserted-by":"publisher","first-page":"30087","DOI":"10.34172\/bi.2024.30087","volume":"14","author":"M Samareh Salavatipour","year":"2024","unstructured":"Samareh Salavatipour, M., Poursalehi, Z., Hosseini Rouzbahani, N., Mohammadyar, S. & Vasei, M. CRISPR-Cas9 in basic and translational aspects of cancer therapy. Bioimpacts 14, 30087 (2024).","journal-title":"Bioimpacts"},{"key":"32228_CR33","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.ccell.2024.05.013","volume":"42","author":"SN Geels","year":"2024","unstructured":"Geels, S. N. et al. Interruption of the intratumor CD8\u2009+\u2009T cell:treg crosstalk improves the efficacy of PD-1 immunotherapy. Cancer Cell. 42, 1051\u20131066e7 (2024).","journal-title":"Cancer Cell."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32228-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32228-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32228-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:10:39Z","timestamp":1769213439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32228-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["32228"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-32228-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of the Mengchao Hepatobiliary Hospital of Fujian Medical University (IRB: MCHH-AEC-2024-009). All experimental procedures strictly followed the ARRIVE guidelines and applicable legal requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"2497"}}